Paper42864656PubMed
Plerixafor and G-CSF Versus Placebo and G-CSF in Moderately Mobilizing Patients With Multiple Myeloma to Optimize Hematopoietic Stem Cell Collection Results (OPTIMIZE).
Nina W and 17 others. J Clin Apher, 2026.
Cite this record
ConductScience Library. Plerixafor and G-CSF Versus Placebo and G-CSF in Moderately Mobilizing Patients With Multiple Myeloma to Optimize Hematopoietic Stem Cell Collection Results (OPTIMIZE). Papers, record 42864656. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42864656
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Plerixafor and G-CSF Versus Placebo and G-CSF in Moderately Mobilizing Patients With Multiple Myeloma to Optimize Hematopoietic Stem Cell Collection Results (OPTIMIZE).
- Journal
- J Clin Apher
- Year
- 2026
- Publication types
- Journal Article, Randomized Controlled Trial
- Revised in PubMed
- 2026-10-15
Source PubMed
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Multiple Myeloma | Major topic |
| Cyclams | Major topic |
| Benzylamines | Major topic |
| Hematopoietic Stem Cell Mobilization | Major topic |
| Granulocyte Colony-Stimulating Factor | Major topic |
| Heterocyclic Compounds | Major topic |
| Humans | |
| Female | |
| Male | |
| Middle Aged | |
| Double-Blind Method | |
| Aged | |
| Antigens, CD34 | |
| Hematopoietic Stem Cell Transplantation | |
| Transplantation, Autologous | |
| Adult | |
| Hematopoietic Stem Cells |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| Sanofi Genzyme | PubMed |
Source PubMed
References26
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27042837 | Multi-color immune-phenotyping of CD34 subsets reveals unexpected differences between various stem cell sources. | Bone Marrow Transplant | 2016 | https://conductscience.org/library/papers/27042837 | PubMed |
| 2 | 21658047 | Efficacy and cost-benefit analysis of risk-adaptive use of plerixafor for autologous hematopoietic progenitor cell mobilization. | Transfusion | 2012 | https://conductscience.org/library/papers/21658047 | PubMed |
| 3 | 17994119 | AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. | Bone Marrow Transplant | 2008 | https://conductscience.org/library/papers/17994119 | PubMed |
| 4 | 34686447 | Second Autologous Stem Cell Transplant as Salvage in Multiple Myeloma - The Oregon Health and Science University Experience. | Clin Lymphoma Myeloma Leuk | 2022 | https://conductscience.org/library/papers/34686447 | PubMed |
| 5 | 37655597 | Impact of daratumumab on stem cell mobilization and collection, engraftment and early post-transplant complications among multiple myeloma patients undergoing autologous stem cell transplantation. | Leuk Lymphoma | 2023 | https://conductscience.org/library/papers/37655597 | PubMed |
| 6 | 38084760 | Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. | N Engl J Med | 2024 | https://conductscience.org/library/papers/38084760 | PubMed |
| 7 | 41862439 | Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium. | Blood Cancer J | 2026 | https://conductscience.org/library/papers/41862439 | PubMed |
| 8 | 24686988 | Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation. | Bone Marrow Transplant | 2014 | https://conductscience.org/library/papers/24686988 | PubMed |
| 9 | 21410373 | Multiple myeloma. | N Engl J Med | 2011 | https://conductscience.org/library/papers/21410373 | PubMed |
| 10 | 24141007 | Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. | Biol Blood Marrow Transplant | 2014 | https://conductscience.org/library/papers/24141007 | PubMed |
| 11 | 27578390 | Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure. | J Clin Apher | 2017 | https://conductscience.org/library/papers/27578390 | PubMed |
| 12 | 38361116 | Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma. | Bone Marrow Transplant | 2024 | https://conductscience.org/library/papers/38361116 | PubMed |
| 13 | 25540889 | Multiple myeloma. | Lancet | 2015 | https://conductscience.org/library/papers/25540889 | PubMed |
| 14 | 39638882 | Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myeloma. | Bone Marrow Transplant | 2025 | https://conductscience.org/library/papers/39638882 | PubMed |
| 15 | 37300386 | Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations. | Blood | 2023 | https://conductscience.org/library/papers/37300386 | PubMed |
| 16 | 23179838 | Colony forming cell assays for human hematopoietic progenitor cells. | Methods Mol Biol | 2013 | https://conductscience.org/library/papers/23179838 | PubMed |
| 17 | 22001752 | Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide. | Biol Blood Marrow Transplant | 2012 | https://conductscience.org/library/papers/22001752 | PubMed |
| 18 | 28580637 | Influence of plerixafor on the mobilization of CD34+ cell subpopulations and lymphocyte subtypes. | Transfusion | 2017 | https://conductscience.org/library/papers/28580637 | PubMed |
| 19 | 19363221 | Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. | Blood | 2009 | https://conductscience.org/library/papers/19363221 | PubMed |
| 20 | 21625224 | Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo. | Bone Marrow Transplant | 2012 | https://conductscience.org/library/papers/21625224 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42864656
GET https://conductscience.org/api/papers/v1/42864656/references?page=2